Haemostasis is a complex process that helps to keep the blood in a fluid state and prevent blood loss at the site of injury. While the intact endothelium of blood vessels has an anti-thrombogenic function that prevents blood coagulation, in the case of vessel wall damage, the exposed sub-endothelial components initiate the formation of a clot that will stop blood loss.
The detection of blast cells in the peripheral blood is considered extremely important, and great responsibility is placed on the investigating laboratory. As well as informa¬tion on the physiology, this SEED article describes the possible causes of the release of blast cells into the blood, the char¬acteristics by which they can be identified and how further diagnosis is carried out.
In this clinical case report a patient presented with a dimorphic RBC population after having received multiple RBC concentrates. The two populations, one resulting from the donor cells, can be identified from two distinct peaks in the RBC histogram.
Being diagnosed with haematologic malignancy actually happens either because the patient presents with certain symptoms or – as is becoming increasingly common – there are incidental findings during routine blood screening. This white paper describes how a complete blood count measured on Sysmex XN-Series analysers may reveal significant abnormalities and improve the incidental findings of haematologic malignancies or the relapse of cancer under treatment early on.
Doping with blood, erythropoietin or related substances is an unfair practice in sports and is performed to obtain an advantage over competing athletes. Doping control has made great progress in detecting the use of forbidden substances by employing completely new strategies that no longer rely on the detection of the banned substance itself. What is measured instead are the changes that forbidden doping practice has on haematological parameters.
Chronic kidney disease (CKD) is a severe complication in context of various civilisation diseases, such as diabetes, hypertension, and obesity. With increasing treatment cost along the progression of CKD towards end-stage renal failure (ESRF) and the need for renal replacement therapies, CKD is not only a driver of premature mortality and diminished quality of life of affected individuals, but also puts significant burden on the society and healthcare expenditures. The early detection of kidney damage through a frequent screening of risk patients could help to fight the burden of CKD. Cost-efficient routine urinalysis data could play a vital role in providing valuable information for screening, diagnosing, and monitoring of renal disorders.